Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
Quick links
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
Contact Contact Investor Relations
E-mail alerts Sign up for E-mail Alerts
PODCAST Investor Relations Podcast
  RSS RSS

Investor Relations

Welcome to the Merck Investor Center
This site is designed to provide analysts and investors (institutional or retail) with quick and easy access to reliable, accurate and current information about Merck. Here you will find information on; historical company earnings, webcasts, presentations, transcripts, SEC filings, stock information and partnership information. For additional information, please visit About Merck.

News
06/27/2008 Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study
06/27/2008 Schering-Plough And Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
06/26/2008 The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Concludes Review of ARCOXIA™ (etoricoxib)
06/25/2008 CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ®, Merck's Rotavirus Vaccine
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
Printer Friendly Page
 

Stock Quote

Latest prices for Merck stock Stock quote (opens new window)

VIOXX Withdrawal

Information on the voluntary withdrawal of
VIOXX® (rofecoxib)

2007 Annual Review

2007 Annual Review: Achieving Results. Accelerating Discovery. Regaining Leadership.

Corporate Responsibility

Corporate Responsibility

Read report

Corporate Governance

Focusing on the Company's strategic and operational excellence and on the best interests of our shareholders

Merck Pipeline

A summary of the company's research pipeline
 
Contact Merck Site Map Privacy Policy Terms of Use Copyright 1995-2008 Merck & Co., Inc.